Expanding partnerships with leading companies in Japan and overseas

「Offices have been established in the United States and China to vigorously promote local partnering negotiations and business development.」

「In March 2025, the company entered into a license agreement with Beijing Yijie Pharmaceutical Technology Co., Ltd. relating to TLG-001 in China.」

「We continue discussions with domestic and overseas partner companies toward licensing agreements.」

「As part of its international expansion, the company became the first Japanese company to open an office in Eye Valley in Wenzhou, Zhejiang Province, and its representative, Tsubota Kazuo (坪田 一男), became a visiting professor in the Department of Ophthalmology at Wenzhou Medical University. In May 2025, the company opened a US office near Seattle, Washington, and is preparing for full-scale expansion into the US market.」

「Business development in China’s high-potential market made rapid progress. The company became the first Japanese company to open an office in Eye Valley in Wenzhou, Zhejiang Province, the national center of myopia research in China, and its representative, Tsubota Kazuo (坪田 一男), became a visiting professor in the Department of Ophthalmology at Wenzhou Medical University. In September, the company also entered into a patent license agreement covering specified regions with Shenyang Xingqi Pharmaceutical Co., Ltd., a leading Chinese ophthalmic pharmaceutical manufacturer.」

「The company achieved a milestone under its license agreement with JINS Holdings Co., Ltd. In addition, it entered into an intellectual property license agreement with Rohto Pharmaceutical Co., Ltd. covering intellectual property rights and R&D results relating to eye drops held, and to be held in the future, by the company.」

「Strengthening the out-licensing of intellectual property and R&D with partner companies serving as joint research partners」

「The company also focused on commodity development in the healthcare field. In August, a personal computer equipped with violet-light LEDs was launched by NECパーソナルコンピュータ株式会社 under a patent and other implementation and use license agreement with the company.」

「In June, the company exhibited at the 2023 BIO International Convention, the world’s largest business-matching event, held in Boston, Massachusetts, presenting its proprietary expertise, technologies and product portfolio to the global market.」

「In business development, we will continue working to strengthen business development by maintaining appropriate communication with many leading domestic and overseas companies in order to conduct joint R&D.」

「In business development, following the commencement of the confirmatory clinical trial for TLG-001, a medical device for suppressing myopia using violet-light technology, the Company achieved a milestone under a domestic licensing agreement and entered into a new licensing agreement covering North and South America. For TLM-003, an eye drop that suppresses the progression of myopia, it also achieved a milestone under the joint research and development agreement and entered into a new licensing agreement covering the United States and Europe.」

「The company has strengthened the out-licensing of intellectual property and R&D with partner companies that serve as joint research partners.」

「In R&D, the Company continued basic research aimed at discovering new intellectual property and adding new pipelines, out-licensing intellectual property, and strengthening R&D with partner companies conducting joint research.」

「In domestic business development, we will continue working to strengthen business development by maintaining appropriate communication with many leading domestic companies in order to conduct joint R&D. In overseas business development, myopia, dry eye and presbyopia are major challenges shared worldwide, so we will work to strengthen business development by building partnerships with leading overseas companies and conducting joint R&D.」